Lv0
0 积分 2023-10-11 加入
Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis
13小时前
待确认
Predicting worsening risk in MGFA class I, II and III myasthenia gravis patients: development and validation of a predictive nomogram
14小时前
已完结
Perioperative Safety and Efficacy of Efgartigimod for Thymoma associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial
14小时前
求助中
Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab
15小时前
已完结
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
9天前
已完结
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
13天前
已完结
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
13天前
已完结
The emerging role of complement in neuromuscular disorders
29天前
已完结
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
1个月前
已完结
The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center
1个月前
已完结
皖公网安备34019202002308
